Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SBC Medical Group Holdings (SBCWW) EBITDA (2023 - 2025)

Historic EBITDA for SBC Medical Group Holdings (SBCWW) over the last 3 years, with Q3 2025 value amounting to $6.0 million.

  • SBC Medical Group Holdings' EBITDA fell 7442.06% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.9 million, marking a year-over-year decrease of 4125.63%. This contributed to the annual value of $30.1 million for FY2024, which is 1308.77% up from last year.
  • According to the latest figures from Q3 2025, SBC Medical Group Holdings' EBITDA is $6.0 million, which was down 7442.06% from $11.1 million recorded in Q2 2025.
  • SBC Medical Group Holdings' 5-year EBITDA high stood at $31.3 million for Q1 2025, and its period low was -$11.6 million during Q4 2024.
  • Its 3-year average for EBITDA is $9.6 million, with a median of $8.6 million in 2024.
  • The largest annual percentage gain for SBC Medical Group Holdings' EBITDA in the last 5 years was 232639.48% (2024), contrasted with its biggest fall of 15496.55% (2024).
  • SBC Medical Group Holdings' EBITDA (Quarter) stood at $21.0 million in 2023, then tumbled by 154.97% to -$11.6 million in 2024, then skyrocketed by 152.29% to $6.0 million in 2025.
  • Its EBITDA stands at $6.0 million for Q3 2025, versus $11.1 million for Q2 2025 and $31.3 million for Q1 2025.